X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
male (29) 29
adult (24) 24
female (24) 24
middle aged (24) 24
respiratory system (23) 23
asthma (21) 21
copd (20) 20
aged (17) 17
index medicus (17) 17
pulmonary disease, chronic obstructive - drug therapy (16) 16
treatment outcome (14) 14
basic electric elements (13) 13
double-blind method (13) 13
electric solid state devices not otherwise provided for (13) 13
electricity (13) 13
general tagging of cross-sectional technologies spanning over several sections of the ipc (13) 13
general tagging of new technological developments (13) 13
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (13) 13
semiconductor devices (13) 13
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (13) 13
technologies or applications for mitigation or adaptation againstclimate change (13) 13
obstructive pulmonary-disease (12) 12
bronchodilator agents - therapeutic use (10) 10
child (10) 10
germany (10) 10
indacaterol (10) 10
lung diseases, obstructive (9) 9
tiotropium (9) 9
administration, inhalation (8) 8
adolescent (8) 8
analysis (8) 8
bronchodilation (8) 8
bronchodilator agents - adverse effects (8) 8
chemistry (8) 8
climate change mitigation technologies in the production orprocessing of goods (8) 8
climate change mitigation technologies related to wastewatertreatment or waste management (8) 8
disposal of solid waste (8) 8
ferrous or non-ferrous alloys (8) 8
forced expiratory volume (8) 8
inflammation (8) 8
metallurgy (8) 8
performing operations (8) 8
pretreatment of raw materials (8) 8
production and refining of metals (8) 8
reclamation of contamined soil soil (8) 8
respiratory tract diseases (8) 8
time factors (8) 8
transporting (8) 8
treatment of alloys or non-ferrous metals (8) 8
asthma - drug therapy (7) 7
cross-over studies (7) 7
curriculum (7) 7
drug administration schedule (7) 7
pharmacology & pharmacy (7) 7
pulmonary disease, chronic obstructive - physiopathology (7) 7
quinolones - adverse effects (7) 7
research (7) 7
safety (7) 7
sputum - chemistry (7) 7
sputum - cytology (7) 7
airway inflammation (6) 6
care and treatment (6) 6
chronic obstructive pulmonary disease (6) 6
diseases of the respiratory system (6) 6
efficacy (6) 6
forced expiratory volume - drug effects (6) 6
indans - adverse effects (6) 6
indans - therapeutic use (6) 6
induced sputum (6) 6
lung - physiopathology (6) 6
pulmonary and respiratory medicine (6) 6
pulmonary disease, chronic obstructive - diagnosis (6) 6
quinolones - administration & dosage (6) 6
quinolones - therapeutic use (6) 6
spirometry (6) 6
allergy (5) 5
asthma - physiopathology (5) 5
bronchodilator agents - administration & dosage (5) 5
cardiac & cardiovascular systems (5) 5
child, preschool (5) 5
clinical trials (5) 5
deficiency (5) 5
dosage and administration (5) 5
drug therapy (5) 5
glutathione (5) 5
indans - administration & dosage (5) 5
lung - drug effects (5) 5
neutrophils (5) 5
original research (5) 5
pharmacokinetics (5) 5
tiotropium bromide (5) 5
adrenergic beta-2 receptor agonists - adverse effects (4) 4
adrenergic beta-2 receptor agonists - therapeutic use (4) 4
adrenergic beta-agonists - therapeutic use (4) 4
asthma - immunology (4) 4
bronchodilators (4) 4
exacerbations (4) 4
glutathione - analysis (4) 4
immunology (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 4, pp. 584 - 592
Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2 -agonist indacaterol... 
Pulmonary/Respiratory | QVA149 | Tiotropium | Chronic obstructive pulmonary disease | Exercise | Hyperinflation | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | DAILY NVA237 | EFFICACY | SAFETY | BRONCHODILATION | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TWICE-DAILY SALMETEROL | ONCE-DAILY INDACATEROL | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Indans - therapeutic use | Lung Volume Measurements | Vital Capacity - drug effects | Quinolones - adverse effects | Spirometry - methods | Quinolones - therapeutic use | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Cross-Over Studies | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Confidence intervals | Drug therapy
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 16, pp. 3206 - 3214
textabstractThe Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000)... 
Journal Article
BLOOD, ISSN 0006-4971, 04/2010, Volume 115, Issue 16, pp. 3206 - 3214
Journal Article
Advances in Therapy, ISSN 0741-238X, 07/2009, Volume 26, Issue 7, pp. 691 - 699
Journal Article
International Journal of COPD, ISSN 1176-9106, 2018, Volume 13, pp. 3923 - 3936
Background and purpose: Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective than the individual components... 
Indacaterol | Once-daily inhalers | Laba/ics combinations | Mometasone | Fixed-combination inhalers | COPD | VILANTEROL | once-daily inhalers | PHARMACOLOGICAL CHARACTERIZATION | MOMETASONE FUROATE | LABA/ICS combinations | OBSTRUCTIVE PULMONARY-DISEASE | IN-VITRO | indacaterol | PHARMACOKINETICS | RESPIRATORY SYSTEM | ONCE-DAILY INDACATEROL | EXACERBATIONS | FIXED-DOSE COMBINATION | fixed-combination inhalers | DURATION | mometasone | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Mometasone Furoate - adverse effects | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Adrenal Cortex Hormones - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Bronchodilator Agents - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Treatment Outcome | Lung - physiopathology | Adrenal Cortex Hormones - adverse effects | Lung - drug effects | Quality of Life | Aged | Health Status | Drug Combinations | Mometasone Furoate - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Corticosteroids | Research | Drug therapy, Combination | Comparative analysis
Journal Article
Journal Article
Thorax, ISSN 0040-6376, 12/2012, Volume 67, Issue Suppl 2, p. A26
Introduction and Objective Aclidinium bromide is a novel, long-acting, muscarinic antagonist indicated as a maintenance treatment for chronic obstructive... 
Journal Article
COPD: Journal of Chronic Obstructive Pulmonary Disease, ISSN 1541-2555, 8/2013, Volume 10, Issue 4, pp. 511 - 522
Journal Article
Advances in Therapy, ISSN 0741-238X, 03/2010, Volume 27, Issue 3, pp. 150 - 159
Journal Article